Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

RegulatoryapprovedPositive

AI Analysis

Summary

Zai Lab Limited received EMA Orphan Drug Designation for a DLL3-targeting cancer therapy, providing regulatory incentives for development of this potentially rare disease treatment.

Outcome Details

EMA Orphan Drug Designation granted

Importance:6/10

Sentiment:

0.70

EMAorphan drug designationoncologyDLL3regulatory milestone

Related Companies

$ZLAB

Read the original article

Published by yahoo_finance on June 30, 2026 1:07 PM

Read Original